Narcan, a nasal spray product that reverses the effects of opioid overdose, is now FDA approved for non-prescription use. Other recent FDA approvals include decisions for drugs from Pharming Group, Incyte, and Aurion Biotech.
Virtual reality has evolved from being a technological novelty to a legitimate clinical tool in areas like chronic pain management and neurological rehab, leading experts to think through how best to integrate VR into healthcare.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Recently, the San Francisco-based health plan reported positive results that showed a 56 percent reduction in overall opioid use among members with chronic, non-cancer pain from 2014 levels.
The $50,000 challenge was sponsered by the Robert Wood Johnson Foundation to help find a tech-enabled approach to addressing substance abuse of opioids.
Despite being just four years old, Centrexion, which just raised $67 million, is building a significant pipeline of non-opioid, non-steroidal pain medications.
As the opioid crisis continues to be top of mind in America, Yale New Haven Health, Yale School of Medicine, Appriss Health and the State of Connecticut have teamed up to better tackle abuse.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Electronic prescribing of controlled substances (EPCS) is finally gaining momentum, but there are common misconceptions.
The move is prompting worry from some physicians who say it could have the unintended consequence of keeping appropriate medical treatment from people with chronic pain.
Investigative journalism lives in some unlikely places, such as on HBO's "Last Week Tonight with John Oliver." This week, host John Oliver — you know, a comedian by trade — took a deep look at the opioid epidemic in America.
In one of the first looks at privately insured patients with opioid problems, researchers paint a grim picture: Medical services for people with opioid dependence diagnoses skyrocketed more than 3,000 percent between 2007 and 2014.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The Kaiser survey also examined Americans’ views on issues involving access to mental health services.
Modifications from generic drugmakers could, say, make these drugs harder to crush and snort, smoke or dissolve to inject intravenously, as seen in a new FDA draft guidance.
What was once just a very useful medication in hospitals for those in pain could now be the source of the next real life 'Breaking Bad' scenario.